Financial Ratios Chison Medical Technologies Co., Ltd.
Equities
688358
CNE1000076R4
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.73 CNY | -0.63% |
|
-2.74% | +15.38% |
| 12-15 | Chison Medical Technologies Delays Two IPO-Funded Projects | MT |
| 12-03 | Certain A Shares of Chison Medical Technologies Co., Ltd. are subject to a Lock-Up Agreement Ending on 3-DEC-2025. | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
Profitability | |||||||||
Return on Assets | 3.89 | 3.29 | 2.84 | 4.69 | 4.03 | ||||
Return on Total Capital | 4.35 | 3.7 | 3.23 | 5.28 | 4.47 | ||||
Return On Equity % | 8.43 | 9.22 | 8.27 | 10.92 | 10.07 | ||||
Return on Common Equity | 8.43 | 9.22 | 8.27 | 10.92 | 10.07 | ||||
Margin Analysis | |||||||||
Gross Profit Margin % | 58.21 | 55.03 | 57.83 | 56.94 | 57.98 | ||||
SG&A Margin | 17.08 | 19.14 | 21.49 | 17.41 | 19.76 | ||||
EBITDA Margin % | 26.97 | 20.34 | 20.38 | 25.86 | 23.84 | ||||
EBITA Margin % | 24.83 | 18.28 | 17.51 | 23.66 | 21.54 | ||||
EBIT Margin % | 24.68 | 18.16 | 17.39 | 23.56 | 21.44 | ||||
Income From Continuing Operations Margin % | 29.91 | 28.27 | 27.79 | 30.27 | 29.98 | ||||
Net Income Margin % | 29.91 | 28.27 | 27.79 | 30.27 | 29.98 | ||||
Net Avail. For Common Margin % | 29.91 | 28.27 | 27.79 | 30.27 | 29.98 | ||||
Normalized Net Income Margin | 18.99 | 13.41 | 17.77 | 19.16 | 19.64 | ||||
Levered Free Cash Flow Margin | 5.61 | 2.5 | -4.27 | -1.07 | 22.11 | ||||
Unlevered Free Cash Flow Margin | 5.61 | 2.51 | -4.25 | -1.03 | 22.16 | ||||
Asset Turnover | |||||||||
Asset Turnover | 0.25 | 0.29 | 0.26 | 0.32 | 0.3 | ||||
Fixed Assets Turnover | 9.65 | 5.64 | 3.29 | 3.45 | 3.11 | ||||
Receivables Turnover (Average Receivables) | 2.82 | 3.02 | 3.28 | 3.88 | 2.96 | ||||
Inventory Turnover (Average Inventory) | 1.96 | 1.95 | 1.08 | 1.25 | 1.5 | ||||
Short Term Liquidity | |||||||||
Current Ratio | 9.85 | 9.09 | 7.1 | 9.69 | 8.42 | ||||
Quick Ratio | 9.11 | 8.33 | 5.97 | 8.58 | 7.58 | ||||
Operating Cash Flow to Current Liabilities | 0.64 | 0.29 | 0.34 | 0.62 | 0.84 | ||||
Days Sales Outstanding (Average Receivables) | 129.58 | 121.03 | 111.4 | 94.14 | 123.62 | ||||
Days Outstanding Inventory (Average Inventory) | 187.2 | 187.25 | 336.82 | 291.59 | 243.69 | ||||
Average Days Payable Outstanding | 128.08 | 113.5 | 103.22 | 196.98 | 132.1 | ||||
Cash Conversion Cycle (Average Days) | 188.7 | 194.78 | 345 | 188.75 | 235.21 | ||||
Long Term Solvency | |||||||||
Total Debt/Equity | - | 0.11 | 0.47 | 0.76 | 0.46 | ||||
Total Debt / Total Capital | - | 0.11 | 0.46 | 0.75 | 0.46 | ||||
LT Debt/Equity | - | 0.06 | 0.44 | 0.46 | 0.19 | ||||
Long-Term Debt / Total Capital | - | 0.06 | 0.44 | 0.46 | 0.19 | ||||
Total Liabilities / Total Assets | 11.61 | 10.91 | 13.24 | 10.08 | 11.05 | ||||
EBIT / Interest Expense | - | 1.06K | 603.27 | 319.06 | 265.26 | ||||
EBITDA / Interest Expense | - | 1.19K | 715.62 | 357.47 | 303.07 | ||||
(EBITDA - Capex) / Interest Expense | - | 618.19 | 240.01 | 262.29 | 279.7 | ||||
Total Debt / EBITDA | - | 0.02 | 0.08 | 0.08 | 0.06 | ||||
Net Debt / EBITDA | -11.66 | -12.58 | -13 | -7.98 | -9.53 | ||||
Total Debt / (EBITDA - Capex) | - | 0.03 | 0.23 | 0.11 | 0.06 | ||||
Net Debt / (EBITDA - Capex) | -17.76 | -24.22 | -38.76 | -10.87 | -10.33 | ||||
Growth Over Prior Year | |||||||||
Total Revenues, 1 Yr. Growth % | -9.92 | 19.43 | -4.27 | 27.04 | -3.13 | ||||
Gross Profit, 1 Yr. Growth % | -13.24 | 12.92 | 0.6 | 25.09 | -1.36 | ||||
EBITDA, 1 Yr. Growth % | -18.24 | -10.5 | -4.82 | 59.83 | -11.1 | ||||
EBITA, 1 Yr. Growth % | -20.68 | -12.66 | -9.1 | 69.85 | -12.23 | ||||
EBIT, 1 Yr. Growth % | -20.37 | -12.12 | -8.33 | 72.17 | -11.88 | ||||
Earnings From Cont. Operations, 1 Yr. Growth % | -5.23 | 12.88 | -5.89 | 38.39 | -4.08 | ||||
Net Income, 1 Yr. Growth % | -5.23 | 12.88 | -5.89 | 38.39 | -4.08 | ||||
Normalized Net Income, 1 Yr. Growth % | -7.1 | -15.66 | 26.85 | 37.01 | -0.74 | ||||
Diluted EPS Before Extra, 1 Yr. Growth % | -26.47 | 12.79 | -6 | 41.49 | -5.26 | ||||
Accounts Receivable, 1 Yr. Growth % | 17.97 | 7.71 | -31.14 | 65.25 | 4.62 | ||||
Inventory, 1 Yr. Growth % | 44.21 | 18.26 | 98.04 | -30.99 | -7.06 | ||||
Net Property, Plant and Equip., 1 Yr. Growth % | 105.97 | 103.35 | 45.35 | 4.3 | 10.11 | ||||
Total Assets, 1 Yr. Growth % | 4.58 | 3.59 | 8.29 | 0.57 | 4.89 | ||||
Tangible Book Value, 1 Yr. Growth % | 1.97 | 4.62 | 5.59 | 4.38 | 3.87 | ||||
Common Equity, 1 Yr. Growth % | 1.89 | 4.42 | 5.45 | 4.23 | 3.76 | ||||
Cash From Operations, 1 Yr. Growth % | 3.28 | -51.53 | 59.51 | 34.78 | 63.76 | ||||
Capital Expenditures, 1 Yr. Growth % | 296.34 | 26.88 | 33.24 | -34.86 | -73.97 | ||||
Levered Free Cash Flow, 1 Yr. Growth % | -38.44 | -46.82 | -383.09 | -68.16 | -3.73K | ||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -38.44 | -46.59 | -379.81 | -69.41 | -4.05K | ||||
Dividend Per Share, 1 Yr. Growth % | -20.01 | -37.5 | 96.02 | 14.29 | 25 | ||||
Compound Annual Growth Rate Over Two Years | |||||||||
Total Revenues, 2 Yr. CAGR % | 0.93 | 3.72 | 6.93 | 10.28 | 10.94 | ||||
Gross Profit, 2 Yr. CAGR % | -0.82 | -1.02 | 6.58 | 12.18 | 11.08 | ||||
EBITDA, 2 Yr. CAGR % | -7.56 | -14.19 | -7.35 | 23.89 | 19.46 | ||||
EBITA, 2 Yr. CAGR % | -9.14 | -16.48 | -10.51 | 24.91 | 22.38 | ||||
EBIT, 2 Yr. CAGR % | -8.98 | -16.35 | -10.25 | 25.63 | 23.17 | ||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 2.38 | 3.43 | 3.07 | 14.12 | 15.22 | ||||
Net Income, 2 Yr. CAGR % | 2.38 | 3.43 | 3.07 | 14.12 | 15.22 | ||||
Normalized Net Income, 2 Yr. CAGR % | -0.34 | -11.49 | 3.43 | 31.83 | 16.61 | ||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -11.05 | -8.93 | 2.6 | 15.33 | 15.78 | ||||
Accounts Receivable, 2 Yr. CAGR % | 55.66 | 12.72 | -13.88 | 6.68 | 31.49 | ||||
Inventory, 2 Yr. CAGR % | 18.6 | 30.59 | 53.04 | 16.91 | -19.91 | ||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 44.98 | 104.66 | 71.92 | 23.13 | 7.17 | ||||
Total Assets, 2 Yr. CAGR % | 104.25 | 4.08 | 5.91 | 4.35 | 2.71 | ||||
Tangible Book Value, 2 Yr. CAGR % | 151.97 | 3.29 | 5.1 | 4.98 | 4.12 | ||||
Common Equity, 2 Yr. CAGR % | 138.81 | 3.14 | 4.93 | 4.84 | 4 | ||||
Cash From Operations, 2 Yr. CAGR % | 7.45 | -29.25 | -12.07 | 46.62 | 48.56 | ||||
Capital Expenditures, 2 Yr. CAGR % | 131.34 | 124.25 | 30.02 | -6.84 | -58.82 | ||||
Levered Free Cash Flow, 2 Yr. CAGR % | -33.14 | -42.78 | -6.79 | -4.88 | 152.09 | ||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -33.14 | -42.66 | -6.99 | -7.3 | 152.91 | ||||
Dividend Per Share, 2 Yr. CAGR % | - | -29.29 | 10.68 | 49.68 | 19.52 | ||||
Compound Annual Growth Rate Over Three Years | |||||||||
Total Revenues, 3 Yr. CAGR % | 7.04 | 6.76 | 0.99 | 13.25 | 5.62 | ||||
Gross Profit, 3 Yr. CAGR % | 6.65 | 3.56 | -0.48 | 12.42 | 7.47 | ||||
EBITDA, 3 Yr. CAGR % | 5 | -8.36 | -10.94 | 11.45 | 11.07 | ||||
EBITA, 3 Yr. CAGR % | 4.22 | -10.12 | -13.84 | 11.19 | 11.22 | ||||
EBIT, 3 Yr. CAGR % | 4.07 | -10.04 | -13.76 | 11.52 | 11.62 | ||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 15.87 | 5.77 | 0.22 | 13.71 | 7.7 | ||||
Net Income, 3 Yr. CAGR % | 15.87 | 5.77 | 0.22 | 13.71 | 7.7 | ||||
Normalized Net Income, 3 Yr. CAGR % | 14.46 | -5.73 | -0.21 | 13.59 | 19.93 | ||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 5.32 | -3.73 | -8.18 | 14.2 | 8.01 | ||||
Accounts Receivable, 3 Yr. CAGR % | 43.97 | 37.68 | -4.35 | 7.02 | 5.99 | ||||
Inventory, 3 Yr. CAGR % | 21.55 | 18.48 | 50.04 | 17.36 | 8.3 | ||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 28.92 | 62.29 | 82.6 | 45.54 | 18.63 | ||||
Total Assets, 3 Yr. CAGR % | 78.38 | 62.89 | 5.47 | 4.1 | 4.53 | ||||
Tangible Book Value, 3 Yr. CAGR % | 114.21 | 87.97 | 4.05 | 4.86 | 4.61 | ||||
Common Equity, 3 Yr. CAGR % | 102.26 | 81.25 | 3.91 | 4.7 | 4.48 | ||||
Cash From Operations, 3 Yr. CAGR % | 9.85 | -17.6 | -7.23 | 1.38 | 52.13 | ||||
Capital Expenditures, 3 Yr. CAGR % | 29.6 | 89.36 | 88.52 | 3.27 | -39.09 | ||||
Levered Free Cash Flow, 3 Yr. CAGR % | 17.84 | -38.05 | -18.83 | -34.76 | 162.37 | ||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 17.84 | -37.96 | -18.94 | -35.71 | 161.92 | ||||
Dividend Per Share, 3 Yr. CAGR % | - | - | -0.67 | 11.87 | 40.95 | ||||
Compound Annual Growth Rate Over Five Years | |||||||||
Total Revenues, 5 Yr. CAGR % | - | 18.96 | 6.99 | 8.15 | 4.86 | ||||
Gross Profit, 5 Yr. CAGR % | - | 18.25 | 6.62 | 6.93 | 3.99 | ||||
EBITDA, 5 Yr. CAGR % | - | 23.95 | 0 | 3.55 | 0.34 | ||||
EBITA, 5 Yr. CAGR % | - | 25.74 | -1.81 | 2.7 | -0.65 | ||||
EBIT, 5 Yr. CAGR % | - | 25.63 | -1.91 | 2.82 | -0.54 | ||||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | 29.85 | 10.57 | 9.03 | 5.97 | ||||
Net Income, 5 Yr. CAGR % | - | 29.85 | 10.57 | 9.03 | 5.97 | ||||
Normalized Net Income, 5 Yr. CAGR % | - | 26.43 | 9.91 | 7.8 | 6.21 | ||||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | 22.55 | 4.23 | 3.34 | 0.74 | ||||
Accounts Receivable, 5 Yr. CAGR % | - | 40.26 | 17.22 | 24.32 | 8.63 | ||||
Inventory, 5 Yr. CAGR % | - | 19.76 | 33.28 | 17.85 | 16.72 | ||||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | 34.73 | 44.66 | 45.32 | 47.54 | ||||
Total Assets, 5 Yr. CAGR % | - | 55.65 | 44.8 | 36.31 | 4.35 | ||||
Tangible Book Value, 5 Yr. CAGR % | - | 75.24 | 61.12 | 48.9 | 4.08 | ||||
Common Equity, 5 Yr. CAGR % | - | 74.8 | 55.56 | 45.61 | 3.94 | ||||
Cash From Operations, 5 Yr. CAGR % | - | -1.06 | 0.49 | 3.76 | 12 | ||||
Capital Expenditures, 5 Yr. CAGR % | - | 39.35 | 29.77 | 42.58 | 2.59 | ||||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | 7.29 | -34.12 | 27.82 | ||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | 7.2 | -34.69 | 27.88 | ||||
Dividend Per Share, 5 Yr. CAGR % | - | - | - | - | 6.96 |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















